Compare $CLRB vs $EGRX | Chartloom

Compare

$CLRB vs $EGRX

Cellectar Biosciences Inc · Eagle Pharmaceuticals Inc

CLRB

Cellectar Biosciences Inc

EGRX

Eagle Pharmaceuticals Inc

Compare $CLRB vs $EGRX

Comparing Cellectar Biosciences Inc and Eagle Pharmaceuticals Inc

CLRBCellectar Biosciences Inc

EGRXEagle Pharmaceuticals Inc

CLRBCellectar Biosciences Inc

Market cap

$12M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-58.2%

52W performance

-69.7%

FCF yield

-168.2%

EGRXEagle Pharmaceuticals Inc

Market cap

$13M

P/E (TTM)

1.06x

Forward P/E (NTM)

0.25x

Forward P/S (NTM)

0.05x

Rev growth (TTM)

-5.4%

YTD performance

185.3%

52W performance

49.2%

FCF yield

-74.5%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CLRB

EGRX

Detailed metrics comparison

CLRB

Cellectar Biosciences Inc

EGRX

Eagle Pharmaceuticals Inc

Market Cap

CLRB$12M

EGRX$13M

Enterprise Value

CLRB$-22M

EGRX$67M

Price

CLRB$1.45

EGRX$0.97

P/E Ratio

CLRBN/A

EGRX1.06x

P/S Ratio

CLRB186.94x

EGRX0.05x

EV/Sales

CLRB-190.77x

EGRX0.26x

EV/EBITDA

CLRB0.00x

EGRX1.07x

P/B Ratio

CLRB0.56x

EGRX0.05x

P/FCF Ratio

CLRBN/A

EGRXN/A

EV/FCF

CLRB1.15x

EGRX-7.18x

PEG Ratio

CLRBN/A

EGRXN/A

Forward P/E (NTM)

CLRBN/A

EGRX0.25x

Forward P/S (NTM)

CLRBN/A

EGRX0.05x

Revenue (TTM)

CLRB$0

EGRX$258M

Revenue Growth (YoY)

CLRBN/A

EGRX-5.4%

Forward Rev Growth

CLRB585.7%

EGRX0.0%

Gross Margin (TTM)

CLRB0.0%

EGRX69.9%

Operating Margin (TTM)

CLRB0.0%

EGRX14.0%

EBITDA Margin (TTM)

CLRB0.0%

EGRX24.5%

Net Margin (TTM)

CLRB0.0%

EGRX4.7%

FCF Margin (TTM)

CLRBN/A

EGRX-3.6%

Net Income (TTM)

CLRB$-22M

EGRX$12M

FCF (TTM)

CLRB$-19M

EGRX$-9M

EPS (TTM)

CLRB-$1.83

EGRX$0.92

ROE (TTM)

CLRB-16571.0%

EGRX5.0%

ROA (TTM)

CLRB-11542.0%

EGRX3.0%

ROIC (TTM)

CLRB-16571.0%

EGRX3.9%

Cash

CLRB$34M

EGRX$15M

Debt

CLRB$0

EGRX$70M

Net Cash/Debt

CLRB$34M

EGRX$-55M

Current Ratio (TTM)

CLRB6.66x

EGRX2.16x

Quick Ratio (TTM)

CLRB6.49x

EGRX1.52x

Debt/Equity (TTM)

CLRB0.00x

EGRX0.28x

Debt/Assets (TTM)

CLRB0.0%

EGRX0.0%

Interest Coverage (TTM)

CLRBN/A

EGRXN/A

Net Debt/EBITDA (TTM)

CLRB0.00x

EGRX0.00x

Beta

CLRB0.58

EGRX0.88

52W Performance

CLRB-69.7%

EGRX49.2%

YTD Performance

CLRB-58.2%

EGRX185.3%

% from 52W High

CLRB-71.4%

EGRX-74.9%

% from 52W Low

CLRB8.2%

EGRX88081.8%

Asset Turnover (TTM)

CLRB0.01x

EGRX0.64x

FCF Yield (TTM)

CLRB-168.2%

EGRX-74.5%

Earnings Yield (TTM)

CLRB-192.7%

EGRX96.0%

Dividend Yield (TTM)

CLRBN/A

EGRXN/A

Rule of 40

CLRB0.0

EGRX-9.0

EV/GP/RG

CLRBN/A

EGRXN/A

Ticker research

View CLRB research View EGRX research

Metric	CLRB Cellectar Biosciences Inc	EGRX Eagle Pharmaceuticals Inc
Market & Valuation
Market Cap	$12M	$13M
Enterprise Value	$-22M	$67M
Price	$1.45	$0.97
P/E Ratio	N/A	1.06x
P/S Ratio	186.94x	0.05x
EV/Sales	-190.77x	0.26x
EV/EBITDA	0.00x	1.07x
P/B Ratio	0.56x	0.05x
P/FCF Ratio	N/A	N/A
EV/FCF	1.15x	-7.18x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	0.25x
Forward P/S (NTM)	N/A	0.05x
Revenue & Growth
Revenue (TTM)	$0	$258M
Revenue Growth (YoY)	N/A	-5.4%
Forward Rev Growth	585.7%	0.0%
Profitability
Gross Margin (TTM)	0.0%	69.9%
Operating Margin (TTM)	0.0%	14.0%
EBITDA Margin (TTM)	0.0%	24.5%
Net Margin (TTM)	0.0%	4.7%
FCF Margin (TTM)	N/A	-3.6%
Net Income (TTM)	$-22M	$12M
FCF (TTM)	$-19M	$-9M
EPS (TTM)	-$1.83	$0.92
ROE (TTM)	-16571.0%	5.0%
ROA (TTM)	-11542.0%	3.0%
ROIC (TTM)	-16571.0%	3.9%
Financial Health
Cash	$34M	$15M
Debt	$0	$70M
Net Cash/Debt	$34M	$-55M
Current Ratio (TTM)	6.66x	2.16x
Quick Ratio (TTM)	6.49x	1.52x
Debt/Equity (TTM)	0.00x	0.28x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.58	0.88
52W Performance	-69.7%	49.2%
YTD Performance	-58.2%	185.3%
% from 52W High	-71.4%	-74.9%
% from 52W Low	8.2%	88081.8%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.64x
FCF Yield (TTM)	-168.2%	-74.5%
Earnings Yield (TTM)	-192.7%	96.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-9.0
EV/GP/RG	N/A	N/A
Ticker research	View CLRB research	View EGRX research

Valuation

P/E Ratio

EGRX

1.06x

P/S Ratio

EGRX

0.05x

CLRB

186.94x

EV/FCF

EGRX

-7.18x

CLRB

1.15x

Growth & revenue

Revenue Growth TTM

EGRX

-5.4%

Forward Revenue Growth

CLRB

585.7%

EGRX

0.0%

Profitability & performance

Gross Margin

EGRX

69.9%

CLRB

0.0%

ROE

EGRX

5.0%

CLRB

-16571.0%

FCF Yield %

EGRX

-74.5%

CLRB

-168.2%

52-Week Performance

EGRX

49.2%

CLRB

-69.7%

Detailed metrics comparison

CLRB

Cellectar Biosciences Inc

EGRX

Eagle Pharmaceuticals Inc

Market Cap

CLRB$12M

EGRX$13M

Enterprise Value

CLRB$-22M

EGRX$67M

Price

CLRB$1.45

EGRX$0.97

P/E Ratio

CLRBN/A

EGRX1.06x

P/S Ratio

CLRB186.94x

EGRX0.05x

EV/Sales

CLRB-190.77x

EGRX0.26x

EV/EBITDA

CLRB0.00x

EGRX1.07x

P/B Ratio

CLRB0.56x

EGRX0.05x

P/FCF Ratio

CLRBN/A

EGRXN/A

EV/FCF

CLRB1.15x

EGRX-7.18x

PEG Ratio

CLRBN/A

EGRXN/A

Forward P/E (NTM)

CLRBN/A

EGRX0.25x

Forward P/S (NTM)

CLRBN/A

EGRX0.05x

Revenue (TTM)

CLRB$0

EGRX$258M

Revenue Growth (YoY)

CLRBN/A

EGRX-5.4%

Forward Rev Growth

CLRB585.7%

EGRX0.0%

Gross Margin (TTM)

CLRB0.0%

EGRX69.9%

Operating Margin (TTM)

CLRB0.0%

EGRX14.0%

EBITDA Margin (TTM)

CLRB0.0%

EGRX24.5%

Net Margin (TTM)

CLRB0.0%

EGRX4.7%

FCF Margin (TTM)

CLRBN/A

EGRX-3.6%

Net Income (TTM)

CLRB$-22M

EGRX$12M

FCF (TTM)

CLRB$-19M

EGRX$-9M

EPS (TTM)

CLRB-$1.83

EGRX$0.92

ROE (TTM)

CLRB-16571.0%

EGRX5.0%

ROA (TTM)

CLRB-11542.0%

EGRX3.0%

ROIC (TTM)

CLRB-16571.0%

EGRX3.9%

Cash

CLRB$34M

EGRX$15M

Debt

CLRB$0

EGRX$70M

Net Cash/Debt

CLRB$34M

EGRX$-55M

Current Ratio (TTM)

CLRB6.66x

EGRX2.16x

Quick Ratio (TTM)

CLRB6.49x

EGRX1.52x

Debt/Equity (TTM)

CLRB0.00x

EGRX0.28x

Debt/Assets (TTM)

CLRB0.0%

EGRX0.0%

Interest Coverage (TTM)

CLRBN/A

EGRXN/A

Net Debt/EBITDA (TTM)

CLRB0.00x

EGRX0.00x

Beta

CLRB0.58

EGRX0.88

52W Performance

CLRB-69.7%

EGRX49.2%

YTD Performance

CLRB-58.2%

EGRX185.3%

% from 52W High

CLRB-71.4%

EGRX-74.9%

% from 52W Low

CLRB8.2%

EGRX88081.8%

Asset Turnover (TTM)

CLRB0.01x

EGRX0.64x

FCF Yield (TTM)

CLRB-168.2%

EGRX-74.5%

Earnings Yield (TTM)

CLRB-192.7%

EGRX96.0%

Dividend Yield (TTM)

CLRBN/A

EGRXN/A

Rule of 40

CLRB0.0

EGRX-9.0

EV/GP/RG

CLRBN/A

EGRXN/A

Ticker research

View CLRB research View EGRX research

Metric	CLRB Cellectar Biosciences Inc	EGRX Eagle Pharmaceuticals Inc
Market & Valuation
Market Cap	$12M	$13M
Enterprise Value	$-22M	$67M
Price	$1.45	$0.97
P/E Ratio	N/A	1.06x
P/S Ratio	186.94x	0.05x
EV/Sales	-190.77x	0.26x
EV/EBITDA	0.00x	1.07x
P/B Ratio	0.56x	0.05x
P/FCF Ratio	N/A	N/A
EV/FCF	1.15x	-7.18x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	0.25x
Forward P/S (NTM)	N/A	0.05x
Revenue & Growth
Revenue (TTM)	$0	$258M
Revenue Growth (YoY)	N/A	-5.4%
Forward Rev Growth	585.7%	0.0%
Profitability
Gross Margin (TTM)	0.0%	69.9%
Operating Margin (TTM)	0.0%	14.0%
EBITDA Margin (TTM)	0.0%	24.5%
Net Margin (TTM)	0.0%	4.7%
FCF Margin (TTM)	N/A	-3.6%
Net Income (TTM)	$-22M	$12M
FCF (TTM)	$-19M	$-9M
EPS (TTM)	-$1.83	$0.92
ROE (TTM)	-16571.0%	5.0%
ROA (TTM)	-11542.0%	3.0%
ROIC (TTM)	-16571.0%	3.9%
Financial Health
Cash	$34M	$15M
Debt	$0	$70M
Net Cash/Debt	$34M	$-55M
Current Ratio (TTM)	6.66x	2.16x
Quick Ratio (TTM)	6.49x	1.52x
Debt/Equity (TTM)	0.00x	0.28x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.58	0.88
52W Performance	-69.7%	49.2%
YTD Performance	-58.2%	185.3%
% from 52W High	-71.4%	-74.9%
% from 52W Low	8.2%	88081.8%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.64x
FCF Yield (TTM)	-168.2%	-74.5%
Earnings Yield (TTM)	-192.7%	96.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-9.0
EV/GP/RG	N/A	N/A
Ticker research	View CLRB research	View EGRX research